Video Insights
Advertisement
Advertisement
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
New therapies, such as TP-3654, are currently being explored in combination studies.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Drs. Winer, Daver, and Abaza discuss the optimal treatment for older patients with AML.
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
Venetoclax plus obinutuzumab was associated with longer PFS compared with chemoimmunotherapy.
There were no significant differences in OS or PFS between allogeneic HSCT and autologous HSCT.
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
The 2024 Society of Hematologic Oncology (SOHO) Annual Meeting will take place September 4-7 in Houston, Texas.
Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.
Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting.
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
Drs. Winer, Daver, and Abaza share their thoughts on the next major breakthroughs in the treatment of AML.
Drs. Winer, Daver, and Abaza share their thoughts and experiences with emavusertib in patients with AML.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Drs. Winer, Daver, and Abaza discuss the major breakthroughs in the treatment of acute myeloid leukemia.
Drs. Winer, Abaza, and Daver discuss their own treatment strategies for patients with AML.
Ola Landgren, MD, PhD, discusses three studies on quadruplet therapy presented at the 2024 ASCO Annual Meeting.
The rate of response was “significantly higher” with asciminib compared with tyrosine kinase inhibitors.
Dr. El-Jawahri discusses exciting ASCO sessions, such as the plenary session that focused on telehealth and palliative care.
The study utilized three clinical trials to compare the efficacy of acalabrutinib, zanubrutinib, and ibrutinib for CLL.
Manali Kamdar, MD, shared results from the pivotal phase III TRANSFORM study on lisocabtagene maraleucel in LBCL.
Himachandana Atluri, MD, describes the experience and ins and outs of becoming a new fellow.
Liso-cel was approved in March 2024 by the FDA for patients with relapsed or refractory CLL.
Prefibrotic myelofibrosis is the focus of “SOHO State of the Art Updates and Next Questions.”
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
